{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:19:28Z","timestamp":1793823568790,"version":"4.6.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Malignant pleural mesothelioma (MPM) is a malevolent tumor originated from pleura and often leads to poor prognosis. Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen by guidelines. However, there are few sustainable second-line anti-tumor theraies that bring distinct survival benefit after the occurrence of drug resistance as the reported mPFS (median progression-free survival) scarcely exceeds 6 months. Immune checkpoint inhibitors are extensively investigated in pan-cancer, and dual immunotherapy has been listed in the first-line recommendation of MPM in several guidelines, while MPM patients benefit modestly from immune checkpoint inhibitors combination or monotherapy in second-line practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnosis:<\/jats:title>\n            <jats:p>We report a 59-year-old male patient who was diagnosed with unresectable MPM in April 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>He received firstly pemetrexed combined with platinum and bevacizumab, which barely curbed disease progression; When the first line treatment failed, he was switched to tislelizumab combined with anlotinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Tislelizumab combined with anlotinib significantly relieved his clinical symptoms, and imaging examination further validated the improvement. Until present, the second-line treatment PFS is more than 10 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The case firstly demonstrated the efficacy of tislelizumab combined with anlotinib in the second-line management of MPM. Thus, immunotherapy combined with small-molecule multi-target anti-angiogenic medication may be alternative for the second-line schemes of MPM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032459","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T13:05:00Z","timestamp":1672405500000},"page":"e32459","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-534X","authenticated-orcid":false,"given":"Dandan","family":"Zhang","sequence":"first","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Liang","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lv","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xikun","family":"Huang","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Guo","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2782590","article-title":"Life expectancy in pleural and peritoneal mesothelioma.","volume":"2017","author":"Shavelle","year":"2017","journal-title":"Lung Cancer Int"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e0145039","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. Sung SY, editor.","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline.","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e000461","DOI":"10.1136\/jitc-2019-000461","article-title":"Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.","volume":"8","author":"Hotta","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies.","volume":"39","author":"Datta","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy.","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.","volume":"69","author":"Yang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle.","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"598877","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities.","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/DDDT.S286529","article-title":"A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.","volume":"15","author":"Cui","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC.","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:26:35Z","timestamp":1746332795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":19,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032459","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}